Immunotherapy prospects for acute myeloid leukaemia

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

1994 • 4,563 citations

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

2005 • 1,715 citations

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

2009 • 1,517 citations

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

2006 • 1,177 citations

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

2004 • 950 citations

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

2009 • 556 citations

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

2004 • 528 citations

The CTL's kiss of death

1995 • 504 citations

Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation

2009 • 470 citations

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

2005 • 446 citations

Natural Killer Cells and Cancer

2003 • 432 citations

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

2008 • 427 citations

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies

2007 • 337 citations

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

2009 • 298 citations

Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD47

1999 • 285 citations

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

2009 • 281 citations

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

2009 • 216 citations

CD8 ⁺ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells

1999 • 215 citations

Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment

2001 • 176 citations

Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia

2007 • 175 citations

Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strains

2008 • 165 citations

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

2009 • 143 citations

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

2002 • 138 citations

Increased population of CD4⁺CD25^high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients

2005 • 134 citations

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

2010 • 133 citations

Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia

2009 • 130 citations

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

2008 • 129 citations

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

2008 • 125 citations

Absolute lymphocyte count is a novel prognostic indicator in ALL and AML

2007 • 123 citations

The L4F3 antigen is expressed by unipotent and multipotent colony- forming cells but not by their precursors

1986 • 119 citations

A robust xenotransplantation model for acute myeloid leukemia

2009 • 118 citations

Identification of natural killer cell receptor phenotypes associated with leukemia

2004 • 117 citations

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

2009 • 116 citations

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

2005 • 116 citations

Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia

1994 • 114 citations

Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial

2009 • 107 citations

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate

2009 • 106 citations

Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient

1977 • 101 citations

Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation

1997 • 97 citations

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

2009 • 97 citations

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

2009 • 93 citations

The DNA demethylating agent 5‐aza‐2′‐deoxycytidine activates NY‐ESO‐1 antigenicity in orthotopic human glioma

2008 • 92 citations

Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.

2006 • 91 citations

Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups

2005 • 90 citations

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes

2008 • 88 citations

Understanding and harnessing the graft‐versus‐leukaemia effect

2008 • 88 citations

Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33⁺ Primary Resistant or Relapsed Acute Myeloid Leukemia

2008 • 84 citations

Phase I/II study of vaccination with dendritic‐like leukaemia cells for the immunotherapy of acute myeloid leukaemia

2006 • 83 citations

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes

2003 • 81 citations

Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells

2010 • 79 citations

Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia

2003 • 79 citations

Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia

2001 • 77 citations

Therapy of acute myelogenous leukemia.

1987 • 77 citations

Glucocorticoid-Induced Tumor Necrosis Factor Receptor–Related Protein Ligand Subverts Immunosurveillance of Acute Myeloid Leukemia in Humans

2009 • 74 citations

Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism

2009 • 70 citations

Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

2010 • 68 citations

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines

2009 • 67 citations

Expression of co‐stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission

2003 • 67 citations

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

2008 • 61 citations

The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

2009 • 59 citations

WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells

2007 • 52 citations

Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia

2001 • 52 citations

CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy

2008 • 52 citations

Post‐consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin‐2 in AML

2009 • 51 citations

Immunotherapy of Acute Myeloid Leukemia: Current Approaches

2009 • 50 citations

The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia

1997 • 49 citations

Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells

2008 • 49 citations

Clinical‐grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation

2008 • 47 citations

Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation

2006 • 46 citations

Unfavourable clinical implications for HLA‐G expression in acute myeloid leukaemia

2008 • 43 citations

Translational Mini-Review Series on Vaccines:
Peptide vaccines for myeloid leukaemias

2007 • 43 citations

Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases

2008 • 42 citations

Adding low‐dose gemtuzumab ozogamicin to fludarabine, Ara‐C and idarubicin (MY‐FLAI) may improve disease‐free and overall survival in elderly patients with non‐M3 acute myeloid leukaemia: results of a prospective, pilot, multi‐centre trial and comparison with a historical cohort of patients

2007 • 42 citations

Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1–reactive cytotoxic T cells

2008 • 42 citations

Does chemotherapy modify the immune surveillance of hematological malignancies?

2008 • 41 citations

B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells

2009 • 41 citations

Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: A pilot study

1990 • 38 citations

Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia

2007 • 36 citations

Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group.

1998 • 35 citations

PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.

2007 • 31 citations

Acute myeloid leukaemia relapsing following interleukin‐2 treatment expresses the alpha chain of the interleukin‐2 receptor

1991 • 31 citations

Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response

2009 • 30 citations

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

2009 • 30 citations

T‐Lymphocyte Functions in Acute Leukaemia Patients with Severe Chemotherapy‐Induced Cytopenia: Characterization of Clonogenic T‐Cell Proliferation

1998 • 30 citations

Activation of autologous leukemia‐specific T cells in acute myeloid leukemia: monocyte‐derived dendritic cells cocultured with leukemic blasts compared with leukemia‐derived dendritic cells

2008 • 27 citations

Reduced levels of recent thymic emigrants in acute myeloid leukemia patients

2008 • 27 citations

Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8+ CD62L(high)+ T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rγnull mice

2008 • 26 citations

Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts

2002 • 25 citations

Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia

1998 • 25 citations

Peptide vaccines for patients with acute myeloid leukemia

2009 • 25 citations

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

2009 • 24 citations

Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes

2009 • 24 citations

Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.

1983 • 23 citations

Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin‐2

1991 • 20 citations

Low dose interleukin‐2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission

2008 • 19 citations

Dendritic cell vaccines in acute leukaemia

2008 • 18 citations

A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies

2008 • 14 citations

Can we include vaccines with stem-cell transplantation?

2009 • 12 citations

The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells

2008 • 12 citations

Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells

2008 • 12 citations

Antibody Therapy for Acute Myeloid Leukemia

2008 • 11 citations

The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders

2009 • 11 citations

CD80 (B7-1) expression on human acute myeloid leukaemic cells cultured with GM-CSF, IL-3 and IL-6

2001 • 10 citations

Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine

2007 • 10 citations

Fusion of Dendritic Cells and CD34+CD38− Acute Myeloid Leukemia (AML) Cells Potentiates Targeting AML-initiating Cells by Specific CTL Induction

2009 • 10 citations

The Endosteum Region Keeps Human Leukemic Stem Cells Alive

2007 • 8 citations

The Combination of Chemotherapy and Systemic Immunotherapy and the Concept of Cure in Murine Leukemia and Lymphoma

2002 • 7 citations

Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures

2009 • 6 citations

Impaired bone marrow lymphocyte proliferation in acute myelogenous leukemia

1979 • 1 citations